LEXICON PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
LEXICON PHARMACEUTICALS, INC. (LXRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.34M, a 4.41% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.08M, a 1.15% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.44M, a 22.99% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.19M, a 34.25% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $12.52M, a 7.27% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $13.50M, a 5.86% decline from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $14.34M, a 24.48% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $11.52M, a 8.92% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.34M 10-Q · filed 2026-08-06 | $6.41M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $3.08M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $12.52M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $3.44M 10-Q · filed 2025-11-06 | $6.64M derived: sum of 2 quarters · filed 2026-08-06 | $9.68M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $3.19M 10-Q · filed 2026-08-06 | $6.24M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $3.04M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $13.50M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $2.80M 10-Q · filed 2025-11-06 | $7.66M derived: sum of 2 quarters · filed 2025-11-06 | $11.96M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $4.86M 10-Q · filed 2025-11-06 | $9.16M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $4.30M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $14.34M 10-K · filed 2026-03-05 | |||
| 2023-09-30 | $3.90M 10-Q · filed 2024-11-13 | $7.71M derived: sum of 2 quarters · filed 2024-11-13 | $11.13M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $3.81M 10-Q · filed 2024-11-13 | $7.23M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $3.42M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $11.52M 10-K · filed 2025-03-07 | |||
| 2022-09-30 | $2.65M 10-Q · filed 2023-11-08 | $5.48M derived: sum of 2 quarters · filed 2023-11-08 | $8.25M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $2.83M 10-Q · filed 2023-11-08 | $5.60M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $2.77M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $10.58M 10-K · filed 2024-03-25 | |||
| 2021-09-30 | $2.71M 10-Q · filed 2022-11-09 | $5.50M derived: sum of 2 quarters · filed 2022-11-09 | $8.35M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $2.79M 10-Q · filed 2022-11-09 | $5.64M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $2.85M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $13.27M 10-K · filed 2023-03-03 | |||
| 2020-09-30 | $1.90M 10-Q · filed 2021-11-09 | $6.16M derived: sum of 2 quarters · filed 2021-11-09 | $10.59M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $4.26M 10-Q · filed 2021-11-09 | $8.69M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $4.43M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $14.22M 10-K · filed 2022-03-10 | |||
| 2019-09-30 | $3.56M 10-Q · filed 2020-10-30 | $7.33M derived: sum of 2 quarters · filed 2020-10-30 | $10.74M derived: sum of 3 quarters · filed 2020-10-30 | $13.59M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $3.77M 10-Q · filed 2020-10-30 | $3.41M 10-Q · filed 2019-11-07 | $10.02M derived: sum of 3 quarters · filed 2021-03-12 | $12.90M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $3.41M 10-Q · filed 2020-10-30 | $6.26M derived: sum of 2 quarters · filed 2021-03-12 | $9.13M derived: sum of 3 quarters · filed 2021-03-12 | $12.03M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $5.72M derived: sum of 2 quarters · filed 2021-03-12 | $8.62M derived: sum of 3 quarters · filed 2021-03-12 | $11.70M 10-K · filed 2021-03-12 |
| 2018-09-30 | $2.88M 10-Q · filed 2019-11-07 | $5.78M derived: sum of 2 quarters · filed 2019-11-07 | $8.85M 10-Q · filed 2018-11-01 | $11.11M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $2.90M 10-Q · filed 2019-11-07 | $5.97M 10-Q · filed 2018-07-30 | $8.23M derived: sum of 3 quarters · filed 2020-03-12 | $10.81M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $3.07M 10-Q · filed 2019-11-07 | $5.33M derived: sum of 2 quarters · filed 2020-03-12 | $7.91M derived: sum of 3 quarters · filed 2020-03-12 | $10.31M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $4.84M derived: sum of 2 quarters · filed 2020-03-12 | $7.24M derived: sum of 3 quarters · filed 2020-03-12 | $9.47M 10-K · filed 2020-03-12 |
| 2017-09-30 | $2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $4.98M derived: sum of 2 quarters · filed 2018-11-01 | $7.21M 10-Q · filed 2018-11-01 | $8.94M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30 | $4.63M 10-Q · filed 2018-07-30 | $6.36M derived: sum of 3 quarters · filed 2019-03-15 | $8.29M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $2.23M 10-Q · filed 2018-05-03 | $3.96M derived: sum of 2 quarters · filed 2019-03-15 | $5.89M derived: sum of 3 quarters · filed 2019-03-15 | $7.85M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $3.66M derived: sum of 2 quarters · filed 2019-03-15 | $5.62M derived: sum of 3 quarters · filed 2019-03-15 | $7.45M 10-K · filed 2019-03-15 |
| 2016-09-30 | $1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $3.89M derived: sum of 2 quarters · filed 2017-11-08 | $5.72M 10-Q · filed 2017-11-08 | $7.15M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $3.79M 10-Q · filed 2017-08-01 | $5.22M derived: sum of 3 quarters · filed 2018-03-01 | $6.89M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $1.83M 10-Q · filed 2017-05-04 | $3.27M derived: sum of 2 quarters · filed 2018-03-01 | $4.94M derived: sum of 3 quarters · filed 2018-03-01 | $6.72M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $3.10M derived: sum of 2 quarters · filed 2018-03-01 | $4.89M derived: sum of 3 quarters · filed 2018-03-01 | $6.84M 10-K · filed 2018-03-01 |
| 2015-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $3.46M derived: sum of 2 quarters · filed 2016-11-07 | $5.41M 10-Q · filed 2016-11-07 | $6.91M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $3.74M 10-Q · filed 2016-08-04 | $5.24M derived: sum of 3 quarters · filed 2017-03-06 | $6.73M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | $1.95M 10-Q · filed 2016-05-05 | $3.45M derived: sum of 2 quarters · filed 2017-03-06 | $4.94M derived: sum of 3 quarters · filed 2017-03-06 | $6.78M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $2.99M derived: sum of 2 quarters · filed 2017-03-06 | $4.83M derived: sum of 3 quarters · filed 2017-03-06 | $7.08M 10-K · filed 2017-03-06 |
| 2014-09-30 | $1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $3.33M derived: sum of 2 quarters · filed 2015-11-09 | $5.58M 10-Q · filed 2015-11-09 | $7.28M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $4.09M 10-Q · filed 2015-08-07 | $5.78M derived: sum of 3 quarters · filed 2016-03-11 | $7.53M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $2.25M 10-Q · filed 2015-05-05 | $3.94M derived: sum of 2 quarters · filed 2016-03-11 | $5.69M derived: sum of 3 quarters · filed 2016-03-11 | $7.56M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $3.44M derived: sum of 2 quarters · filed 2016-03-11 | $5.31M derived: sum of 3 quarters · filed 2016-03-11 | $7.42M 10-K · filed 2016-03-11 |
| 2013-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $3.62M derived: sum of 2 quarters · filed 2014-11-06 | $5.73M 10-Q · filed 2014-11-06 | $7.32M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $3.98M 10-Q · filed 2014-08-07 | $5.57M derived: sum of 3 quarters · filed 2015-03-12 | $7.16M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $2.11M 10-Q · filed 2014-05-08 | $3.70M derived: sum of 2 quarters · filed 2015-03-12 | $5.29M derived: sum of 3 quarters · filed 2015-03-12 | $6.89M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $3.18M derived: sum of 2 quarters · filed 2015-03-12 | $4.78M derived: sum of 3 quarters · filed 2015-03-12 | $6.50M 10-K · filed 2015-03-12 |
| 2012-09-30 | $1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $3.19M derived: sum of 2 quarters · filed 2013-11-12 | $4.91M 10-Q · filed 2013-11-12 | $6.26M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $3.31M 10-Q · filed 2013-08-01 | $4.67M derived: sum of 3 quarters · filed 2014-03-07 | $6.10M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-03-31 | $1.72M 10-Q · filed 2013-05-10 | $3.07M derived: sum of 2 quarters · filed 2014-03-07 | $4.50M derived: sum of 3 quarters · filed 2014-03-07 | $5.95M derived: sum of 4 quarters · filed 2014-03-07 |
| 2011-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $2.79M derived: sum of 2 quarters · filed 2014-03-07 | $4.24M derived: sum of 3 quarters · filed 2014-03-07 | $5.71M 10-K · filed 2014-03-07 |
| 2011-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $2.88M derived: sum of 2 quarters · filed 2012-11-07 | $4.35M 10-Q · filed 2012-11-07 | $5.51M derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $2.92M 10-Q · filed 2012-08-02 | $4.08M derived: sum of 3 quarters · filed 2013-03-11 | $5.41M derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-03-31 | $1.47M 10-Q · filed 2012-05-03 | $2.63M derived: sum of 2 quarters · filed 2013-03-11 | $3.96M derived: sum of 3 quarters · filed 2013-03-11 | |
| 2010-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $2.49M derived: sum of 2 quarters · filed 2013-03-11 | $5.12M 10-K · filed 2013-03-11 | |
| 2010-09-30 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | $3.96M 10-Q · filed 2011-11-01 | ||
| 2010-06-30 | $2.63M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $5.64M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |